Capabilities

Acquisition of NextWave Pharmaceuticals

Pfizer

Our attorneys represented Pfizer Inc. in connection with its acquisition of NextWave Pharmaceuticals, the developer of Quillivant XR™, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. 

Email Disclaimer